The shares of the Micro-Cap company, specializing in manufacturing and exporting finished pharmaceutical formulations in various dosage forms, hit a 20 percent upper circuit upon declaring Q4 results with a 243 percent rise in Profit (YoY).
With a market capitalization of Rs. 999.28 crores on Tuesday, the shares of Kwality Pharmaceuticals Ltd hit a 20 percent upper circuit, making a high of Rs. 990.90 per share compared to its previous closing price of Rs. 825.75 per share.
Kwality Pharmaceuticals Ltd, specializing in manufacturing and exporting finished pharmaceutical formulations in various dosage forms, has announced its Q4 results as follows.
Its Revenue from operations rose by 26 percent YoY from Rs. 92.0 Crores in Q4FY24 to Rs. 116 Crores in Q4FY25, and it rose by 37.4 percent QoQ from Rs. 84.4 Crores in Q3FY25 to Rs. 116 Crores in Q4FY25.
Its Net profit rose by 243 percent from Rs. 4.23 Crores in Q4FY24 to Rs. 14.5 Crores in Q4FY25, and it rose by 70.1 percent QoQ from a profit of Rs. 8.52 Crores in Q3FY25 to Rs. 14.5 Crores in Q4FY25. Previous years’ figures have been adjusted, where necessary, to align with the current format. This ensures a fair comparison with the latest results. The earnings per share (EPS) for the quarter stood at Rs. 13.96, compared to Rs. 8.22 in the previous quarter.
The company has a P/E ratio of 24.43, lower than the industry average of 34.33, indicating potential undervaluation. Its PEG ratio of 0.51 supports this view, suggesting strong growth at a reasonable price. Additionally, a low debt-to-equity ratio of 0.43 reflects a healthy financial position.
Guidance & Others
Kwality aims to achieve Rs. 500 crores in revenue, with expected EBITDA margins between 22 percent to 25 percent, reflecting its continued focus on growth.
Kwality Pharmaceuticals Ltd (KPL), established on May 4, 1983, is a leading Indian pharmaceutical company headquartered in Amritsar, Punjab. Specializing in the manufacture of high-quality finished pharmaceutical formulations, KPL offers a diverse product portfolio, including injectables, tablets, capsules, oral liquids, ointments, and effervescents.
The company operates multiple state-of-the-art manufacturing facilities, certified with global quality standards such as WHO-GMP, EU-GMP, and PIC/S GMP, ensuring compliance with international regulatory requirements.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
